Synthesis and Nanoprecipitation of HEMA-CL Based Polymers for the Production of Biodegradable Nanoparticles

Overview

Journal Polymers (Basel)

Publisher MDPI

Date 2019 Apr 11

PMID 30965689

Authors

Simone Gatti

Azzurra Agostini

Raffaele Ferrari

Davide Moscatelli

Affiliations

Soon will be listed here.

Abstract

The control over the size distribution and stability of polymeric nanoparticles (NPs) is crucial in many of their applications, especially in the biomedical field. These characteristics are typically influenced by the production method and the nature of the starting material. To investigate these aspects, the controlled radical polymerization of functionalized methacrylates constituted by 2-hydroxyethyl methacrylate (HEMA) functionalized with a controlled number of ε-caprolactone (CL) units (HEMA-CL), was carried out via reversible addition⁻fragmentation chain transfer polymerization (RAFT) in solution. The living reaction allows for good control over the molar mass of the final polymer with a low molar mass dispersity. The obtained polymer solutions were nanoprecipitated in order to produce NPs suitable for drug delivery applications with narrow particle size distribution and a wide size range (from 60 to 250 nm). The NP synthesis has been performed using a mixing device, in order to control the parameters involved in the nanoprecipitation process. As already seen for similar systems, the size of the produced NPs is a function of the polymer concentration during the nanoprecipitation process. Nevertheless, when the polymer concentration is kept constant, the NP size is influenced by the chemical structure of the polymer used, in terms of the presence of PEG (poly(ethylene glycol)), the degree of RAFT polymerization, and the length of the caprolactone side chain. These characteristics were also found to influence the stability and degradation properties of the produced NPs.

References

Musumeci T, Ventura C, Giannone I, Ruozi B, Montenegro L, Pignatello R . PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006; 325(1-2):172-9. DOI: 10.1016/j.ijpharm.2006.06.023. View

York A, Kirkland S, McCormick C . Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. Adv Drug Deliv Rev. 2008; 60(9):1018-36. DOI: 10.1016/j.addr.2008.02.006. View

Boyer C, Bulmus V, Davis T, Ladmiral V, Liu J, Perrier S . Bioapplications of RAFT polymerization. Chem Rev. 2009; 109(11):5402-36. DOI: 10.1021/cr9001403. View

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

Kedar U, Phutane P, Shidhaye S, Kadam V . Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010; 6(6):714-29. DOI: 10.1016/j.nano.2010.05.005. View

Azzi J, Tang L, Moore R, Tong R, El Haddad N, Akiyoshi T . Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010; 24(10):3927-38. PMC: 2996919. DOI: 10.1096/fj.10-154690. View

Shi J, Votruba A, Farokhzad O, Langer R . Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010; 10(9):3223-30. PMC: 2935937. DOI: 10.1021/nl102184c. View

Elsabahy M, Wooley K . Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012; 41(7):2545-61. PMC: 3299918. DOI: 10.1039/c2cs15327k. View

Couvreur P . Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2012; 65(1):21-3. DOI: 10.1016/j.addr.2012.04.010. View

10.

Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P . Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2012; 42(3):1147-235. DOI: 10.1039/c2cs35265f. View

11.

Harrisson S, Nicolas J, Maksimenko A, Bui D, Mougin J, Couvreur P . Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization. Angew Chem Int Ed Engl. 2012; 52(6):1678-82. DOI: 10.1002/anie.201207297. View

12.

Xia Y, Tang S, Olsen B . Site-specific conjugation of RAFT polymers to proteins via expressed protein ligation. Chem Commun (Camb). 2013; 49(25):2566-8. PMC: 4059823. DOI: 10.1039/c3cc38976f. View

13.

Moad G, Rizzardo E, Thang S . RAFT polymerization and some of its applications. Chem Asian J. 2013; 8(8):1634-44. DOI: 10.1002/asia.201300262. View

14.

Lee H, Bae Y . Brushed block copolymer micelles with pH-sensitive pendant groups for controlled drug delivery. Pharm Res. 2013; 30(8):2077-86. DOI: 10.1007/s11095-013-1060-1. View

15.

Ferrari R, Colombo C, Casali C, Lupi M, Ubezio P, Falcetta F . Synthesis of surfactant free PCL-PEG brushed nanoparticles with tunable degradation kinetics. Int J Pharm. 2013; 453(2):551-9. DOI: 10.1016/j.ijpharm.2013.06.020. View

16.

Ferrari R, Rooney T, Lupi M, Ubezio P, Hutchinson R, Moscatelli D . A methyl methacrylate-HEMA-CL(n) copolymerization investigation: from kinetics to bioapplications. Macromol Biosci. 2013; 13(10):1347-57. DOI: 10.1002/mabi.201300152. View

17.

Mehan S, Chinchalikar A, Kumar S, Aswal V, Schweins R . Small-angle neutron scattering study of structure and interaction of nanoparticle, protein, and surfactant complexes. Langmuir. 2013; 29(36):11290-9. DOI: 10.1021/la402977b. View

18.

Simakova A, Mackenzie M, Averick S, Park S, Matyjaszewski K . Bioinspired iron-based catalyst for atom transfer radical polymerization. Angew Chem Int Ed Engl. 2013; 52(46):12148-51. DOI: 10.1002/anie.201306337. View

19.

Papa S, Rossi F, Ferrari R, Mariani A, De Paola M, Caron I . Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. ACS Nano. 2013; 7(11):9881-95. DOI: 10.1021/nn4036014. View

20.

Colombo C, Morosi L, Bello E, Ferrari R, Licandro S, Lupi M . PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Mol Pharm. 2015; 13(1):40-6. DOI: 10.1021/acs.molpharmaceut.5b00383. View